SCHEMBL5605136

SCHEMBL5605136

CN1CCN(C(=O)CCCC(=O)O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.54
NPC1 O15118 1/20 0.50
KMT2A Q03164 5/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 3/20 0.48
HPGD P15428 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 2/20 0.48
TSHR P16473 1/20 0.48
ITGB3 P05106 2/20 0.47
ITGA2B P08514 2/20 0.47
GNAI3 P08754 3/20 0.46
GNAO1 P09471 3/20 0.46
GNAI1 P63096 3/20 0.46
GLA P06280 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HTT P42858 1/20 0.45
TDP1 Q9NUW8 3/20 0.45
CYP1A2 P05177 2/20 0.45
SLC22A6 Q4U2R8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28400652 0.94 GNAI3 (0.53) ATMNPC1KMT2AALDH1A1MEN1
SCHEMBL10883612 0.94 GNAI3 (0.53) ATMNPC1KMT2AALDH1A1MEN1
SCHEMBL3242393 0.88 SMN1; SMN2 (0.51) KMT2AALDH1A1MEN1HPGDSMN1; SMN2
Hydrochloric Acid SCHEMBL27078195 0.86 SMN1; SMN2 (0.50) KMT2AALDH1A1MEN1HPGDSMN1; SMN2
SCHEMBL6493498 0.84 ATM (0.54) ATMNPC1KMT2AALDH1A1MEN1
Hydrochloric Acid SCHEMBL28396748 0.83 ATM (0.48) ATMNPC1KMT2AALDH1A1MEN1
SCHEMBL5605766 0.82 L3MBTL1 (0.49) ATMNPC1KMT2AALDH1A1MEN1
SCHEMBL11240 0.82 L3MBTL1 (0.62) ATMNPC1KMT2AALDH1A1MEN1
SCHEMBL6043354 0.82 ATM (0.50) ATMNPC1KMT2AALDH1A1MEN1
SCHEMBL2732315 0.82 ATM (0.50) ATMNPC1KMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118957804-A Novel composite antibacterial polyester fiber and preparation method thereof 江苏恒科新材料有限公司 2024-11-15 CN claimed
CN-118957804-A Novel composite antibacterial polyester fiber and preparation method thereof 江苏恒科新材料有限公司 2024-11-15 CN disclosed
CN-111194306-B Methods and processes for preparing KDM1A inhibitors 伊美格生物科学公司 2023-05-16 CN disclosed
EP-3741357-A1 AMPHIPHILIC POLYMER SYSTEMS Universitätsspital Basel (CH) 2020-11-25 EP disclosed
CN-111194306-A Methods and processes for preparing KDM1A inhibitors 伊美格生物科学公司 2020-05-22 CN disclosed
EP-3236936-B1 AMPHIPHILIC POLYMER SYSTEMS UNIV BASEL (CH) 2020-02-19 EP disclosed
US-9790499-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9278987-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2016-03-08 US disclosed
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2014-11-06 US disclosed
WO-2013074834-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2013-05-23 WO disclosed
CN-100543032-C Streptogramin derivatives, preparation method and compositions containing them AVETIS PHARMA S A (FR) 2009-09-23 CN disclosed
CN-1961878-A Streptogramin derivatives, their preparation and compositions containing them AVENTIS PHARMA SA (FR) 2007-05-16 CN disclosed
US-7166594-B2 Antibacterial activity AVENTIS PHARMA S.A. (FR) 2007-01-23 US disclosed
US-20030149004-A1 Streptogramin derivatives, their preparation and compositions containing them AVENTIS PHARMA S.A. 2003-08-07 US disclosed
US-6569854-B1 Virginamycins AVENTIS PHARMA S.A. (FR) 2003-05-27 US disclosed
CN-1358194-A Streptogramin derivatives, preparation method and compositions containing them AVETIS PHARMA S A (FR) 2002-07-10 CN disclosed
EP-0499130-A1 DC-89 derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF RTCB, NSUN3, NSUN2 ATM 3539/4885NPC1 3978/4885KMT2A 2877/4885
US-20030149004-A1 Streptogramin derivatives, their preparation and compositions containing them MRPL21, ABHD5, APEH ATM 2840/4885NPC1 2105/4885KMT2A 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.